{
  "id": 19375449,
  "title": "Absci at Guggenheim healthcare conference: pipeline push gains focus",
  "url": "https://urgent.news/2026/11/10/absci-at-guggenheim-healthcare-conference-pipeline-push-gains-focus",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-10T18:37:38.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/absci-at-guggenheim-healthcare-conference-pipeline-push-gains-focus-93CH-5016527"
  },
  "original_language": "en",
  "account": "At the 3rd Annual Guggenheim Healthcare Innovation Conference, Absci Corporation (ABSI) emphasized its shift from an AI drug discovery platform to a biopharmaceutical company focused on building its own antibody therapeutics. The company highlighted two key indications for ABS-201, its lead antibody program: pattern hair loss and endometriosis. Management reported $201 million in cash at the end of Q2 2024, which should sustain operations through the second half of 2028 and cover key clinical milestones. The company expects 13-week interim data from the HEADLINE trial next month and a broader proof-of-concept readout in early 2025.\n\nAbsci positioned ABS-201 as a regenerative therapy, aiming to prevent hair follicle regression by blocking prolactin buildup in hair follicles. This approach differs from maintenance drugs and may offer a more effective and longer-lasting solution. The company reported preclinical results showing sustained hair growth for up to four years after a 28-week dosing period in stump-tailed macaques. ABS-201 is being tested in Phase I-IIa trials for pattern hair loss and endometriosis, with the latter in an undisclosed immunology and inflammation indication. Absci aims for a $25 billion U.S. market opportunity in hair loss, with peak sales potentially exceeding $4 billion for endometriosis. The company also mentioned its $10.02 stock price, down 7.22% from the previous close, and its strong runway through the second half of 2028.",
  "summary": null,
  "key_points": [
    "Absci shifts from AI drug discovery to antibody therapeutics",
    "ABS-201 targets pattern hair loss and endometriosis",
    "$201M cash reserves sustain operations through 2028"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}